# How to Write an Investment Committee Memo for a Healthcare Deal > An investment committee memo for a healthcare deal must go beyond standard financial analysis to address regulatory risk, clinical evidence, reimbursement dynamics, and IP durability. This guide walks through every section with healthcare-specific guidance and primary sources to verify before you write a single word. ## What Is an Investment Committee Memo and Why Does Healthcare Demand a Different Standard? An investment committee (IC) memo is the formal written argument you submit to your fund's decision-makers asking for approval to deploy capital into a specific deal. In healthcare, the stakes for getting it wrong are higher than in most sectors: a missed FDA warning letter, a miscounted patent expiration, or a reimbursement coding change can erase an investment thesis before the ink dries on a term sheet. A strong healthcare IC memo answers every question a skeptical committee member will raise before they raise it, backed by citations from primary sources, not sell-side summaries. The memo should open with a direct recommendation: fund or pass, at what valuation, on what terms, and why now. Every subsequent section either defends or qualifies that recommendation. ## How Should You Structure the Memo Section by Section? **Executive Summary (half a page maximum).** State the company, subsector, proposed check size, ownership percentage, entry valuation, and your investment thesis in plain language. Committees read dozens of memos; if the thesis is not obvious in sixty seconds, you have already lost them. **Company and Market Overview.** Describe what the company actually does in clinical or operational terms, not marketing language. Quantify the addressable market using CMS data, published epidemiology from PubMed, or payer claims data where available. Avoid vendor-supplied TAM figures without triangulation. **Regulatory Status and Risk.** This section separates healthcare memos from all others. Pull the company's FDA establishment registration and device listings directly from the FDA 510(k) and PMA databases at accessdata.fda.gov. For drugs or biologics, check the FDA Drugs@FDA portal for approval history, REMS programs, and any outstanding Complete Response Letters. Search the FDA Warning Letters database for the company name and any contract manufacturers it uses. Document what you found and what you did not find. A clean search is a positive data point worth stating explicitly. **Clinical Evidence Assessment.** Search ClinicalTrials.gov for every registered study. Note trial phases, enrollment status, primary endpoints, and whether results have been posted. Cross-reference against PubMed for peer-reviewed publications. Flag any gap between what the company claims in its pitch deck and what is registered or published. Committees will ask whether efficacy data is from a randomized controlled trial or a single-arm study with no comparator; know the answer before you walk in the room. **Reimbursement and Payor Dynamics.** For a device or diagnostic, identify the relevant CPT or HCPCS code and look up the current Medicare payment rate in the CMS Physician Fee Schedule or the Medicare Clinical Laboratory Fee Schedule. For a drug, check the ASP Drug Pricing File or the Part D formulary landscape. For a hospital-dependent technology, check the DRG assignment and whether there is a New Technology Add-On Payment in place. Reimbursement coverage gaps are one of the most common reasons healthcare companies miss revenue projections, and they are entirely verifiable before you finalize your memo. **Intellectual Property Analysis.** Pull every patent the company cites from the USPTO Patent Full-Text Database at patents.google.com or directly at patft.uspto.gov. Note the expiration date, the independent claims, and whether there are any inter partes review petitions filed against them at the Patent Trial and Appeal Board. For drugs, check the FDA Orange Book to confirm which patents are listed and the Paragraph IV certification history. A patent that expires eighteen months after your projected exit is a material risk. **Financial Model and Return Analysis.** Present a base, bull, and bear case with revenue assumptions tied to the clinical and reimbursement evidence above, not to management guidance alone. Show gross margin trajectory, cash burn runway, and the specific revenue milestone that must be hit to support your exit multiple. Identify comparable public company multiples from recent SEC filings and comparable M&A transactions from public deal disclosures. **Management and Execution Risk.** Verify founder and executive credentials independently. Check SEC EDGAR for any prior enforcement actions or material disclosures tied to key individuals. Review the company's own SEC filings if applicable, particularly the Risk Factors section, which management is legally required to write honestly. **Key Risks and Mitigants.** List the five to seven risks in order of severity, not plausibility. For each risk, name the specific mitigant and whether that mitigant is within your control. Do not bury the most important risk at the bottom. **Recommendation and Proposed Terms.** Restate your recommendation with the valuation methodology, proposed protective provisions, and any conditions to closing such as regulatory diligence or reference checks. ## What Are the Most Common Mistakes Investors Make in Healthcare IC Memos? The most frequent failure is treating regulatory and reimbursement sections as checkboxes rather than substantive analysis. Writing that a product is FDA-cleared without specifying the predicate device, the cleared indications, and any limitations of the clearance letter leaves the committee flying blind. A second common error is modeling revenue as if current reimbursement rates are permanent; CMS reprices codes annually, and a rate cut of twenty to thirty percent can make or break an early-stage commercial-stage company. Third, investors often rely on the company's IP summary rather than reading the actual claims, missing narrowing amendments made during prosecution that materially limit enforceability. ## Healthcare IC Memo Checklist - Clear fund or pass recommendation stated in the first paragraph - FDA database search completed and results documented (accessdata.fda.gov) - All ClinicalTrials.gov registrations reviewed and compared to company claims - Relevant CPT or HCPCS reimbursement rate confirmed from CMS directly - Independent claims of key patents read and expiration dates confirmed - SEC EDGAR search completed for company and key individuals - Three-scenario financial model with assumptions tied to primary sources - Five to seven risks ranked by severity with named mitigants - Proposed terms and conditions to closing stated explicitly ## How Can You Build This Level of Diligence More Efficiently? Verifying all of these primary sources manually across FDA, ClinicalTrials.gov, USPTO, CMS, and EDGAR for a single deal can take a senior analyst three to five full days. MedFuel Intel automates the primary-source verification layer with AI-driven due-diligence reports that surface regulatory flags, patent expiration dates, reimbursement gaps, and clinical evidence quality scores in hours rather than days. Run a free Red Flag Screener on your current deal at https://medfuelintel.com and see exactly which sections of your IC memo need deeper work before you walk into the committee room. --- *Informational only, not investment advice.* --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/how-to-write-an-investment-committee-memo-for-a-healthcare-deal). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.